Methods for Economic Evaluations of Novel Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Methods for Economic Evaluations of Novel Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review
Authors
Keywords
-
Journal
Applied Health Economics and Health Policy
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-29
DOI
10.1007/s40258-023-00842-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CHEERS to Updated Guidelines for Reporting Health Economic Evaluations!
- (2022) Richard J. Willke et al. VALUE IN HEALTH
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force
- (2022) Don Husereau et al. VALUE IN HEALTH
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
- (2022) Don Husereau et al. VALUE IN HEALTH
- Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain
- (2022) Carlos Escobar Cervantes et al. PLoS One
- Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk
- (2022) Ju Hee Choi et al. Frontiers in Cardiovascular Medicine
- Cost Effectiveness of Patient Self-Managed Warfarin Compared with Direct Oral Anticoagulants in Atrial Fibrillation: An Economic Evaluation in a Danish Healthcare Sector Setting
- (2022) Sabine Michelsen Raunbak et al. Pharmacoeconomics-Open
- Cost-Utility Analysis of Dabigatran and Warfarin for Stroke Prevention Among Patients With Nonvalvular Atrial Fibrillation in India
- (2022) Rajeswari Aghoram et al. Value in Health Regional Issues
- Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Economic Evaluations
- (2022) Zahra Goudarzi et al. Value in Health Regional Issues
- Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
- (2021) Hongtao Wei et al. BMC HEALTH SERVICES RESEARCH
- Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available “Real-World” Evidence: The Italian National Health System Perspective
- (2021) Valentina Lorenzoni et al. CLINICAL DRUG INVESTIGATION
- 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
- (2021) Jan Steffel et al. EUROPACE
- Cost-Effectiveness Analysis of Direct Oral Anticoagulants Vs. Vitamin K Antagonists in the Elderly With Atrial Fibrillation: Insights From the Evidence in a Real-World Setting
- (2021) Yue Wu et al. Frontiers in Cardiovascular Medicine
- Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
- (2021) Taru Hallinen et al. ClinicoEconomics and Outcomes Research
- Cost‐effectiveness of anticoagulants for preventing stroke in patients with non‐valvular atrial fibrillation in mainland China
- (2021) Hui Zhou et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain
- (2021) Simone Rivolo et al. PLoS One
- Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis
- (2021) Rini Noviyani et al. BMJ Evidence-Based Medicine
- Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China
- (2020) Shu-Jie Dong et al. CLINICAL THERAPEUTICS
- Predicting Cost‐Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States
- (2020) Ching‐Yu Wang et al. CTS-Clinical and Translational Science
- Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge
- (2020) Giuseppe Lippi et al. International Journal of Stroke
- Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
- (2020) Kevin Bowrin et al. PLoS One
- Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review
- (2020) Koen Degeling et al. PHARMACOECONOMICS
- Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients
- (2020) Evelyn Walter et al. Expert Review of Pharmacoeconomics & Outcomes Research
- 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)
- (2020) Gerhard Hindricks et al. EUROPEAN HEART JOURNAL
- Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles
- (2020) Ching-Yu Wang et al. PHARMACOECONOMICS
- Cost‐effectiveness of rivaroxaban versus warfarin in non‐valvular atrial fibrillation patients with chronic kidney disease in China
- (2020) Lin Liu et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
- (2020) Gregory A. Roth et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation
- (2019) Piyameth Dilokthornsakul et al. Heart Lung and Circulation
- Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
- (2019) Ahmad S. Hersi et al. ANNALS OF SAUDI MEDICINE
- Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
- (2019) Lisa A. de Jong et al. PLoS One
- Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting
- (2019) Masatsugu Hori et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand
- (2019) Siok Shen Ng et al. THROMBOSIS RESEARCH
- Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding
- (2018) Alexa R. Hospodar et al. American Journal of Cardiovascular Drugs
- Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease
- (2018) Shoroq M. Altawalbeh et al. VALUE IN HEALTH
- Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function
- (2018) Jonathan Salcedo et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding
- (2018) Thananan Rattanachotphanit et al. PHARMACOECONOMICS
- Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer’s Disease
- (2018) Estefanía Ruiz Vargas et al. STROKE
- Latin American Clinical Epidemiology Network Series – Paper 2: Apixaban was cost-effective vs. acenocoumarol in patients with nonvalvular atrial fibrillation with moderate to severe risk of embolism in Chile
- (2017) Fernando Lanas et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function
- (2017) Inmaculada Hernandez et al. THROMBOSIS RESEARCH
- Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
- (2017) José A López-López et al. BMJ-British Medical Journal
- Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
- (2017) José A López-López et al. BMJ-British Medical Journal
- The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands
- (2017) Marinus van Hulst et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥65 Years With Nonvalvular Atrial Fibrillation
- (2016) Brian M. Salata et al. AMERICAN JOURNAL OF CARDIOLOGY
- Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
- (2016) Kostas Athanasakis et al. American Journal of Cardiovascular Drugs
- Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
- (2016) Chieh-Yu Liu et al. CLINICAL DRUG INVESTIGATION
- Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation
- (2016) Ying Jiao Zhao et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients
- (2016) Elaine Nguyen et al. PHARMACOTHERAPY
- Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
- (2016) Anuj Shah et al. STROKE
- Persistence and Discontinuation of Oral Anticoagulant: Remaining Issues Not Addressed by Phase III Clinical Trials
- (2016) Kengo Ayabe et al. Journal of the American Heart Association
- Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
- (2016) Taru Hallinen et al. SpringerPlus
- Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses
- (2016) Xue Li et al. PLoS One
- Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF–TIMI 48 trial
- (2015) Elizabeth A. Magnuson et al. AMERICAN HEART JOURNAL
- Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist
- (2015) Misericòrdia Carles et al. BMC HEALTH SERVICES RESEARCH
- Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting
- (2015) Kostas Athanasakis et al. CLINICAL DRUG INVESTIGATION
- Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation
- (2015) Gregory Y.H. Lip et al. CLINICAL THERAPEUTICS
- Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan
- (2015) Isao Kamae et al. CLINICAL THERAPEUTICS
- Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
- (2015) Martin Krejczy et al. Biomed Research International
- Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups
- (2014) Andreas Clemens et al. AMERICAN JOURNAL OF CARDIOLOGY
- Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings
- (2014) Talitha I. Verhoef et al. American Journal of Cardiovascular Drugs
- Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective
- (2014) Julie Chevalier et al. Archives of Cardiovascular Diseases
- Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
- (2014) Ye Wang et al. CARDIOVASCULAR DRUGS AND THERAPY
- Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin
- (2014) Thitima Kongnakorn et al. CLINICAL DRUG INVESTIGATION
- Cost-Utility Analysis of Oral Anticoagulants for Nonvalvular Atrial Fibrillation Patients at the Police General Hospital, Bangkok, Thailand
- (2014) Siriporn Jarungsuccess et al. CLINICAL THERAPEUTICS
- Comparison of the Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation in a UK Setting
- (2014) Ying Zheng et al. CLINICAL THERAPEUTICS
- Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
- (2014) Gregory Y.H. Lip et al. CLINICAL THERAPEUTICS
- Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
- (2014) P. Dorian et al. EUROPEAN HEART JOURNAL
- Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
- (2014) Carla Rognoni et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation
- (2014) Alexander Mensch et al. PHARMACOECONOMICS
- Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control
- (2014) Andrej Janzic et al. PHARMACOECONOMICS
- Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
- (2014) Torbjørn Wisløff et al. PHARMACOECONOMICS
- Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
- (2014) Jelena Stevanović et al. PLoS One
- Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan
- (2014) Chia-Hsien Chang et al. THROMBOSIS RESEARCH
- Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting
- (2014) João Morais et al. Revista Portuguesa de Cardiologia
- Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin
- (2014) T. Lanitis et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
- (2013) James V. Freeman et al. ANNALS OF INTERNAL MEDICINE
- Recent Developments in Understanding Epidemiology and Risk Determinants of Atrial Fibrillation as a Cause of Stroke
- (2013) Yousif Ahmad et al. CANADIAN JOURNAL OF CARDIOLOGY
- Cost–Effectiveness of Different Strategies for Stroke Prevention in Patients with Atrial Fibrillation in a Health Resource-Limited Setting
- (2013) Bin Wu et al. CARDIOVASCULAR DRUGS AND THERAPY
- Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial Fibrillation
- (2013) William J. Canestaro et al.
- Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
- (2013) Carla Rognoni et al. CLINICAL DRUG INVESTIGATION
- Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation
- (2013) J Pink et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Novel Oral Anticoagulants Versus Warfarin Therapy at Various Levels of Anticoagulation Control in Atrial Fibrillation—A Cost-Effectiveness Analysis
- (2013) Joyce H. S. You JOURNAL OF GENERAL INTERNAL MEDICINE
- Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries
- (2013) Martin Krejczy et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation
- (2013) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
- (2013) Joris Kleintjens et al. PHARMACOECONOMICS
- Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Cost-Effectiveness Models
- (2013) Brendan L. Limone et al. PLoS One
- Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
- (2013) Amanda R. Harrington et al. STROKE
- Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland
- (2013) M Pletscher et al. SWISS MEDICAL WEEKLY
- Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation
- (2013) Doug Coyle et al. VALUE IN HEALTH
- Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia
- (2013) Zanfina Ademi et al. European Journal of Preventive Cardiology
- Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium
- (2013) Hanne Wouters et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
- (2012) Thomas Davidson et al. EUROPEAN HEART JOURNAL
- Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
- (2012) Anuraag R Kansal et al. HEART
- COST-EFFECTIVENESS OF RIVAROXABAN COMPARED TO WARFARIN FOR STROKE PROPHYLAXIS IN ATRIAL FIBRILLATION
- (2012) Soyon Lee et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation
- (2012) H. Kamel et al. NEUROLOGY
- Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
- (2012) Soyon Lee et al. PLoS One
- Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
- (2012) Hooman Kamel et al. STROKE
- Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada
- (2012) Michael Sharma et al. THROMBOSIS AND HAEMOSTASIS
- Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark
- (2012) Lars K Langkilde et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
- (2011) Shimoli V. Shah et al. CIRCULATION
- The cost of illness of atrial fibrillation: a systematic review of the recent literature
- (2011) S. E. Wolowacz et al. EUROPACE
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective
- (2011) Anuraag Kansal et al. THROMBOSIS AND HAEMOSTASIS
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now